Composition

Details Composition Composition

2007-05-22

2007-05-22

Salimi, Ali R. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S069700, C435S091330

Reexamination Certificate

active

11477879

ABSTRACT:
Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen,Toxoplasma gondiiantigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

REFERENCES:
patent: 5151023 (1992-09-01), Kuzuhara et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 6123948 (2000-09-01), Whittle et al.
patent: 6251678 (2001-06-01), Volkin et al.
patent: 6451320 (2002-09-01), Stephenne et al.
patent: 6932972 (2005-08-01), Stephenne et al.
patent: EP 689454 (1994-09-01), None
patent: WO 95/17209 (1995-06-01), None
patent: WO 96/26277 (1996-08-01), None
patent: WO 99/10375 (1999-03-01), None
patent: WO 99/45957 (1999-09-01), None
patent: WO 00/15255 (2000-03-01), None
patent: WO 00/23105 (2000-04-01), None
patent: WO 00/44944 (2000-07-01), None
Breitburd et al., Immunization with Virus-Like Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect Against Experimental CRPV Infection, Journal of Virology, vol. 69, (1995), pp. 3959-3963.
U.S. Appl. No. 09/807,657, filed Apr. 16, 2001, Garcon.
U.S. Appl. No. 10/983,451, filed Jun. 9, 2005, Wettendorff.
Harper et al., Lancet, vol. 364, (2004), pp. 1757-1765.
Kirnbauer et al., Papillomavirus L1 Major Capsid Protein Self-Assembles into Virus-Like Particles that are Highly Immunogenic, PNAS, (1992), vol. 89, pp. 12180-12184.
Kirnbauer et al., Virus-Like Particles of Bovine Papillomavirus Type 4 in Prophylactic and Therapeutic Immunization, Virology, vol. 219, (1996), pp. 37-44.
Lowe et al., “Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-Like Particles Expressed in Yeast”, Journal of Infectious Diseases, vol. 176, No. 5, 1997 pp. 1141-1145.
Roden et al., “Assessment of the SerologicalRelatedness of Genital Human Papillomaviruses by Hemagglutination Inhibition”, Journal of Virology, vol. 70, No. 5, May 1996, pp. 3298-3301.
Schiller et al., “Papillomavirus-Like Particles and HPV Vaccine Development”, Seminars in Cancer biology, Saunders Scientific Publications, vol. 7, No. 6, 1996, pp. 373-382.
Speidel, et al., “Priming of Cytotoxic T Lymphocytes by Five Heat-Aggregated Antigens in vivo: Conditions, Efficiency, and Relation to Antibody Responses”, Eur. J. Immunol., 1997, vol. 27, pp. 2391-2399.
Suzich et al., “Systemic immunication with papilomavirus L1 protein completely prevents the development of viral mucosal papillomas”, Proceedings of the National Academy of Sciences of USA, National Academy of Science, vol. 92, 1995, pp. 11553-11557.
Tindle, et al., “Chimeric Hepatitis B Core Antigen Particles Containing B-and The-Epitopes of Human Papillomavirus Type 16 E7 Protein Induce Specific Antibody and T-Helper Responses in Immunised Mice”, Virology 200, 1994, pp. 547-557.
Wheeler, “Preventive Vaccines for Cervical Cancer”, Salud Publica De Mexico, vol. 39, No. 4, Jul. 1997, pp. 283-287.

Affiliated with

Also associated with

Rating

Composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3786387